Lefamulin
Open Access
- 2 January 2020
- journal article
- research article
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 57 (6) , 704-711
Abstract
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.Keywords
This publication has 17 references indexed in Scilit:
- Lefamulin: Review of a Promising Novel Pleuromutilin AntibioticPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial PathogensAntimicrobial Agents and Chemotherapy, 2018
- In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeaeAntimicrobial Agents and Chemotherapy, 2017
- In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and ChinaAntimicrobial Agents and Chemotherapy, 2017
- A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanismScientific Reports, 2016
- In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United StatesAntimicrobial Agents and Chemotherapy, 2016
- Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010Antimicrobial Agents and Chemotherapy, 2013
- Phase II Clinical Study of BC-3781, a Pleuromutilin Antibiotic, in Treatment of Patients with Acute Bacterial Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2013
- Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)Journal of Antimicrobial Chemotherapy, 2012